SEC Filing Summary: Corcept Therapeutics Inc. (CORT)
Business Context and Reporting Period
This Form 8-K was filed by Corcept Therapeutics Incorporated on December 30, 2024. The report covers a specific corporate event occurring on the same date, rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a regulatory submission and does not contain financial statements or performance data.
Material Changes
The material event reported is the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The application is for relacorilant, the Company's proprietary selective cortisol modulator, intended to treat patients with endogenous hypercortisolism (Cushing's syndrome).
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing the NDA submission. No specific financial guidance, management commentary on future performance, or discussion of risks and contingencies is included in the text of this Form 8-K.
Investor Verification Checklist
- Verify the status and expected review timeline of the relacorilant NDA with the FDA.
- Review the full text of the press release attached as Exhibit 99.1 for additional clinical data or indications.
- Monitor subsequent filings for any FDA responses, such as a Complete Response Letter or approval decision.
- Check the Company's most recent 10-K or 10-Q for current financial health and cash runway, as this 8-K contains no financial data.